|
mRNA_ID
|
Gene Name
|
drug_ID
|
drug_Name
|
Disease
|
RNA_exp_pattern
|
Evidence
|
Details
|
|
ENST00000254958
|
E2F1
|
NA
|
Gastrodin
|
vestibular injuries
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
leukemia
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
colorectal cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
ovarian cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
liver cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
prostate cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
osteosarcoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
medullary thyroid carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
clear cell renal cell carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
osteosarcoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
lung adenocarcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
multiple myeloma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
oral squamous cell cancer (oscc)
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
cervical cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
gastric cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
esophageal adenocarcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
malignant melanoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
prostate cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
bladder cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
pancreatic cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
glioma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
oral squamous cell cancer (oscc)
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
glioblastoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
glioblastoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
bladder cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
bladder cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
pancreatic ductal adenocarcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
breast cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
prostate cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
non-small cell lung cancer
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
NA
|
hepatocellular carcinoma
|
up-regulated
|
predicted
|
more...
|
|
ENST00000254958
|
E2F1
|
DB09086
|
Eugenol
|
breast cancer
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB00328
|
Indomethacin
|
ovarian cancer
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB00586
|
Diclofenac
|
ovarian cancer
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB01037
|
Selegiline
|
parkinson＇s disease
|
up-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB05679
|
Ustekinumab
|
psoriasis
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB00051
|
Adalimumab
|
psoriasis
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB00005
|
Etanercept
|
psoriasis
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB12001
|
Abemaciclib
|
endometrial cancer
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB09302
|
Alirocumab
|
alcoholic liver disease
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
DIF-1
|
cancer
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB01169 (APRD00171)
|
Arsenic trioxide
|
mesothelioma
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
NA
|
Piperlongumine
|
acute lymphoblastic leukemia
|
down-regulated
|
validated
|
more...
|
|
ENST00000254958
|
E2F1
|
DB00227 (APRD00370)
|
Lovastatin
|
prostate cancer
|
down-regulated
|
validated
|
more...
|